Australiadrg

AFT Pharmaceuticals (ASX:AFP) posted a 22% rise in full-year operating revenue, reaching NZ$254.7 million, up from NZ$208 million in FY25.

World Health Organization Director-General Tedros Adhanom Ghebreyesus called for an international response to the Ebola outbreak at a meeting of the WHO's emergency committee in Geneva on Tuesday. Bloomberg's Jennifer Zabasajja reports.

Telix Pharmaceuticals (ASX:TLX) completed patient enrolment for its international, multicentre Phase 1 IPAX-2 clinical trial.

US citizens who were on the Hondius cruise ship hit by a hantavirus outbreak are now being isolated in Nebraska. One person is in a specialized biocontainment unit after testing positive for the rare respiratory disease. Shares of Moderna are rising after the company said it's working on a vaccine. Sam Fazeli of Bloomberg Intelligence has more.

Novo Nordisk said this year's declines won't be as bad as initially expected thanks to the new Wegovy pill, which helped fuel sales in the first quarter. For the year, the worst drop for both profit and sales will be 12%, compared with 13% earlier. Bloomberg's Sanne Wass reports from Copenhagen.

Pfizer Inc. Chief Executive Officer Albert Bourla says President Donald Trump's nominee to lead the Centers for Disease Control and Prevention is a good choice. Bourla says Erica Schwartz is a "very credible scientist." Bourla also talks about earnings, their drug pipeline and doing business in China. He speaks to Bloomberg's David Westin.

The US Justice Department is expected to reclassify marijuana into a less restrictive federal category as soon as Wednesday, according to a person familiar with the matter. The change could remove taxes for companies that sell marijuana. Shares of cannabis stocks rose on the news. Nathan Dean of Bloomberg Intelligence has more.

FDA granted Immutep (ASX:IMM) Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma.

AFT Pharmaceuticals (ASX:AFP) recorded sustained double-digit sales growth across its entire global portfolio for the March quarter of 2026.

The US Medicare program will pay private insurers 2.48% more in 2027, a meaningful improvement over the initial rates the agency proposed in January. Michelle Cortez has more on "Bloomberg The Close."